 |
|
|
| |
A multicentre observational study to determine the safety and
effectiveness of dolutegravir (DTG) use during pregnancy:
Data from DOLOMITE-NEAT ID Network study
|
| |
| |
IAC: Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana - (08/01/22)
AIDS 2022 July 29-Aug 1 Montreal
Justyna D. Kowalska1, Sergii Antoniak2, Lambert Assoumou3, Anton Pozniak4, Tetiana Rybak5, Stephane De Wit6 , Ana
Milinkovic4, Sherie Roedling7, Annie Duffy8, Carl Fletcher8, Leigh Ragone9, Claire Thorne10, and Vani Vannappagari9,
on behalf of the DOLOMITE study group
x
1 Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland; 2 Gromashevsky Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine; 3 INSERM, Paris, France; 4 Chelsea & Westminster Hospital,
London, United Kingdom; 5 Odesa Regional Centre of Socially Significant Diseases, Odesa, Ukraine; 6 CHU Saint-Pierre, Brussels, Belgium; 7 Mortimer Market Centre, CNWL NHS Trust, London, United Kingdom; 8 Research
Organisation (Kings Cross) Ltd, London, United Kingdom; 9 ViiV Healthcare, Research Triangle Park, United States; 10 Fondazione Penta Onlus, Italy
|
| |
|
|
|
|
|
